Application segmentation of the Lung AI‑assisted Diagnosis Solution market is organized around four primary use cases: early detection, disease staging, treatment monitoring, and risk stratification. Early detection leverages AI algorithms to identify subtle radiographic patterns indicative of nascent malignancy, driving the largest share of adoption because it directly influences screening program efficiency and reduces downstream treatment costs. Disease staging employs deep‑learning models to quantify tumor size, nodal involvement, and metastasis, supporting clinicians in selecting optimal therapeutic pathways; its market contribution reflects the high value placed on accurate staging for reimbursement and clinical outcomes. Treatment monitoring applies serial imaging analysis to assess response to chemotherapy, radiotherapy, or immunotherapy, thereby sustaining recurring revenue streams through subscription‑based analytics. Risk stratification integrates patient demographics, smoking history, and imaging biomarkers to generate individualized risk scores, enabling preventive interventions and influencing payer coverage decisions. Collectively, these applications constitute the core of the Lung AI‑assisted Diagnosis Solution segmentation, each adding distinct revenue drivers that shape overall market size.